7/4
11:57 am
nbp
NovaBridge: Rebranded, Repackaged, But Far From De-Risked [Seeking Alpha]
Medium
Report
NovaBridge: Rebranded, Repackaged, But Far From De-Risked [Seeking Alpha]
6/29
07:25 am
nbp
NovaBridge Biosciences appoints Srishti Gupta as CEO [Seeking Alpha]
High
Report
NovaBridge Biosciences appoints Srishti Gupta as CEO [Seeking Alpha]
6/29
07:00 am
nbp
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
High
Report
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
6/16
07:27 am
nbp
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer [Yahoo! Finance]
Medium
Report
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer [Yahoo! Finance]
6/16
07:00 am
nbp
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
Low
Report
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
6/3
06:02 am
nbp
I-Mab (NBP) was upgraded by
Weiss Ratings from "sell (e+)" to "sell (d-)".
Low
Report
I-Mab (NBP) was upgraded by
Weiss Ratings from "sell (e+)" to "sell (d-)".
5/28
07:55 am
nbp
Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth [Yahoo! Finance Canada]
Low
Report
Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth [Yahoo! Finance Canada]
5/28
07:00 am
nbp
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
Low
Report
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
5/20
06:02 am
nbp
I-Mab (NBP) was downgraded by
Weiss Ratings from "sell (d-)" to "sell (e+)".
Low
Report
I-Mab (NBP) was downgraded by
Weiss Ratings from "sell (d-)" to "sell (e+)".
5/12
07:00 am
nbp
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Low
Report
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
5/7
06:02 am
nbp
I-Mab (NBP) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Low
Report
I-Mab (NBP) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
4/22
07:00 am
nbp
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
Low
Report
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value